KR100666471B1 - 치매의 예방과 개선 및 기억력 증진용 조성물 및 이를포함하는 건강보조식품 - Google Patents
치매의 예방과 개선 및 기억력 증진용 조성물 및 이를포함하는 건강보조식품 Download PDFInfo
- Publication number
- KR100666471B1 KR100666471B1 KR1020030088177A KR20030088177A KR100666471B1 KR 100666471 B1 KR100666471 B1 KR 100666471B1 KR 1020030088177 A KR1020030088177 A KR 1020030088177A KR 20030088177 A KR20030088177 A KR 20030088177A KR 100666471 B1 KR100666471 B1 KR 100666471B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- dibenzo
- ecklonia
- composition
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000015654 memory Effects 0.000 title claims abstract description 25
- 206010012289 Dementia Diseases 0.000 title claims abstract description 23
- 230000002265 prevention Effects 0.000 title claims description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 14
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 14
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960004373 acetylcholine Drugs 0.000 claims abstract description 14
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 13
- 230000006993 memory improvement Effects 0.000 claims abstract description 10
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical class C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 150000004827 dibenzo-1,4-dioxins Chemical class 0.000 claims description 36
- 239000002858 neurotransmitter agent Substances 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 24
- 241001512723 Ecklonia Species 0.000 claims description 21
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 11
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 8
- 241000741680 Ecklonia arborea Species 0.000 claims description 7
- 241000230129 Eisenia <Phaeophyceae> Species 0.000 claims description 7
- 229940076279 serotonin Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 4
- 241000946389 Ecklonia kurome Species 0.000 claims description 4
- 241000243681 Eisenia bicyclis Species 0.000 claims description 4
- -1 dihydroxyphenyl Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229960002748 norepinephrine Drugs 0.000 claims description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 4
- 241001512722 Ecklonia cava Species 0.000 claims description 3
- 241000439005 Ecklonia stolonifera Species 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 2
- 241000983748 Ecklonia radiata Species 0.000 claims description 2
- 241000653613 Ecklonia radicosa Species 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000003642 hunger Nutrition 0.000 claims description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- 230000037351 starvation Effects 0.000 claims description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- 241001392689 Ecklonia maxima Species 0.000 claims 1
- 241001122767 Theaceae Species 0.000 claims 1
- 235000019994 cava Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 11
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- DRZQFGYIIYNNEC-UHFFFAOYSA-N dieckol Chemical compound OC1=CC(O)=CC(OC=2C=3OC4=C(O)C=C(OC=5C(=CC(OC=6C=7OC8=C(O)C=C(O)C=C8OC=7C(O)=CC=6O)=CC=5O)O)C=C4OC=3C(O)=CC=2O)=C1 DRZQFGYIIYNNEC-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 7
- 229960001231 choline Drugs 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 7
- 229960001685 tacrine Drugs 0.000 description 7
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000006403 short-term memory Effects 0.000 description 6
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000002110 toxicologic effect Effects 0.000 description 5
- 231100000027 toxicology Toxicity 0.000 description 5
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 4
- 229920002036 Dieckol Polymers 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 244000299790 Rheum rhabarbarum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 2
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 229910021397 glassy carbon Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010000659 Choline oxidase Proteins 0.000 description 1
- 244000140640 Diospyros digyna Species 0.000 description 1
- 235000015031 Diospyros digyna Nutrition 0.000 description 1
- 235000001417 Diospyros texana Nutrition 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000011872 anthropometric measurement Methods 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000002988 nephrogenic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000706 no observed effect level Toxicity 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- AIMUHNZKNFEZSN-UHFFFAOYSA-M sodium;decane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCS([O-])(=O)=O AIMUHNZKNFEZSN-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/80—Geriatric
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
시료 | 시료의 조성 | βAPP(%) |
음성대조군 | - | 100 |
1 | I (R=H), 99% | 71.8 |
2 | II (R=H), 98% | 68.3 |
3 | III (R=H), 99% | 63.2 |
4 | IV (R=H), 99% | 56.8 |
5 | V (R=H), 99% | 65.0 |
6 | VI (R=H), 99% | 63.9 |
7 | VII (R=H), 99% | 64.0 |
8 | VIII (R=H), 99% | 56.7 |
9 | IX (R=H), 99% | 49.7 |
10 | X (R=H), 99% | 64.4 |
11 | II (R=H), 60% + III (R=H), 25% + IV (R=H), 15% | 50.7 |
12 | IV (R=H), 70% + V (R=H) 8% + VI (22%) | 63.8 |
13 | IV (R=H), 10% + X (R=H), 80% + VII (R=H), 10% | 61.6 |
14 | I (R=H), 3% + II (R=H), 60% + III (R=H), 10% + IV (R=H), 12% + V (R=H), 5% + VI (R=H), 10% | 60.5 |
15 | II (R=H), 60% + IV (R=H), 20% + VI (R=H), 15% + VII (R=H), 5% | 65.4 |
16 | IV(R=acetyl, H (3:7)) | 73.2 |
17 | II (R=oleoyl, H (1:9) | 73.9 |
18 | VI (R=methyl, H (2:8)) | 75.4 |
양성대조군 | (-)펜세린, 99.9% | 64.8 |
표 1에 나타난 바와 같이, 상기 추출물은 베타아밀로이드 전구체 단백질의 형성을 억제함을 알 수 있는데, 즉, 상기 추출물을 처리하지 않은 음성대조군에 비해(100%) 상기 추출물을 처리한 경우 베타아밀로이드 전구체 단백질의 양이 현저히 줄어들었음(49.7-75.4%)을 알 수 있다. 따라서 상기 추출물은 베타아밀로이드 전구체 단백질의 생성을 억제함으로 치매 예방 및 개선에 효과적임을 확인하였다.
시험대상 | 최초 20명의 환자가 참여하여 17명이 4주간의 시험을 마쳤다. 3명은 4주후 측정시 불참하여 제외되었다. |
시험 시료 | 실시예 1의 조성 #14가 10%(40mg/400mg) 함유된 캡슐 |
복용 방법 | 아침, 저녁으로 식후 2시간 후에 2캡슐씩 |
평가 방법 | 시험시작 전날 및 4주후 최소인지능력시험(Mini-Mental Score Examination)으로 평가하였다. |
통계처리 | 시험전후의 측정치를 Student's t-test를 활용하여 유의성을 평가하였다. |
나이(세) | 71.8±5.6(63~82) | ||
성별 | 남 | 7(41.2%) | |
여 | 10(58.8%) | ||
신장(cm) | 161.6±8.9(149~175) | ||
체중(kg) | 57.0±8.9(45~75) | ||
MMSE | 13.2±3.25(20~46) | *23±4 |
상기 표 3에 나타난 바와 같이 본 발명을 섭취한 후 인지능력 회복실험에 관한 데이터에서 인체계측치(MMSE)가 시험전(13.2±3.25)에 비하여 시험후(23±4) 유의성있게 증가하였다.
Claims (11)
- 디벤조-p-디옥신(dibenzo-p-dioxine) 유도체를 유효성분으로 포함하는 치매의 예방과 개선 및 기억력 증진용 조성물.
- 제 1항에 있어서, 상기 조성물은 베타아밀로이드 전구단백질(β-Amyloid Precursor Protein, βAPP)의 생성을 억제하고, 신경전달물질의 생성을 증가시키는 특성을 갖는 것을 특징으로 하는 조성물.
- 제 2항에 있어서, 상기 신경전달물질은 노르아드레날린, 아세틸콜린, 세로토닌 또는 GABA(γ-aminobutyric acid)임을 특징으로 하는 조성물.
- 제 4항에 있어서, 상기 디벤조-p-디옥신 유도체는 각 화학식에서 R이 H인 것을 특징으로 하는 조성물.
- 제 4항에 있어서, 상기 디벤조-p-디옥신 유도체는 각 화학식에서 R이 H이며 상기 화학식 1 내지 10의 디벤조-p-디옥신 유도체 중 두개 이상 혼합되어 사용되며, 전체 조성물 기준으로 상기 화학식 1의 디벤조-p-디옥신 유도체는 0.1-6중량%, 상기 화학식 2의 디벤조-p-디옥신 유도체는 5-60중량%, 상기 화학식 3의 디벤조-p-디옥신 유도체는 1-30중량%, 상기 화학식 4의 디벤조-p-디옥신 유도체는 0.5-20중량%, 상기 화학식 5의 디벤조-p-디옥신 유도체는 0.1-10중량%, 상기 화학식 6의 디벤조-p-디옥신 유도체는 0.5-15중량%, 상기 화학식 7의 디벤조-p-디옥신 유도체는 0.1-5중량%, 상기 화학식 8의 디벤조-p-디옥신 유도체는 0.1-5중량%, 상기 화학식 9의 디벤조-p-디옥신 유도체는 0.1-10중량%, 그리고 상기 화학식 10의 디벤조-p-디옥신 유도체는 0.1-12중량%로 포함되는 것을 특징으로 하는 조성물.
- 제 1항에 있어서, 상기 디벤조-p-디옥신 유도체는 아이세니아 바시클리스(Eisenia bicyclis), 아이세니아 아르보레아(Eisenia arborea), 아이세니아 데스마레스티오데스(Eisenia desmarestioides), 아이세니아 갈라파제니스(Eisenia galapagensis), 아이세니아 매소니(Eisenia masonii), 에클로니아 쿠로메(Ecklonia kurome), 에클로니아 카바(Ecklonia cava), 에클로니아 스톨로니페라(Ecklonia stolonifera), 에클로니아 맥시마(Ecklonia maxima), 에클로니아 라디아타(Ecklonia radiata), 에클로니아 바이시클리스(Ecklonia bicyclis), 에클로니아 바이런시네이트(Ecklonia biruncinate), 에클로니아 부시날리스(Ecklonia buccinalis), 에클로니아 카에파에스팁스(Ecklonia caepaestipes), 에클로니아 엑사스퍼타(Ecklonia exasperta), 에클로니아 파스티기아타(Ecklonia fastigiata), 에클로니아 브레빕스(Ecklonia brevipes), 에클로니아 아라보레아(Ecklonia arborea), 에클로니아 라티폴리아(Ecklonia latifolia), 에클로니아 무라티(Ecklonia muratii), 에클로니아 라디코사(Ecklonia radicosa), 에클로니아 리타디아나(Ecklonia richardiana) 또는 에클로니아 라이티(Ecklonia wrightii)로부터 추출된 것임을 특징으로 하는 조성물.
- 제 1항에 있어서, 상기 조성물의 일일섭취량은 1-100mg/Kg임을 특징으로 하는 조성물.
- 제 1항에 있어서, 상기 조성물은 캡슐이나 정제 형태를 갖는 것을 특징으로 하는 조성물.
- 제 1항의 조성물을 0.1-100중량% 포함함을 특징으로하는 치매의 예방과 개선 및 기억력 증진에 효과적인 건강보조식품.
- 제 10항에 있어서, 상기 건강보조식품은 캡슐, 정제, 음료 또는 빵류 형태임을 특징으로 하는 건강보조식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030088177A KR100666471B1 (ko) | 2003-12-05 | 2003-12-05 | 치매의 예방과 개선 및 기억력 증진용 조성물 및 이를포함하는 건강보조식품 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030088177A KR100666471B1 (ko) | 2003-12-05 | 2003-12-05 | 치매의 예방과 개선 및 기억력 증진용 조성물 및 이를포함하는 건강보조식품 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050054667A KR20050054667A (ko) | 2005-06-10 |
KR100666471B1 true KR100666471B1 (ko) | 2007-01-09 |
Family
ID=37249919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030088177A KR100666471B1 (ko) | 2003-12-05 | 2003-12-05 | 치매의 예방과 개선 및 기억력 증진용 조성물 및 이를포함하는 건강보조식품 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100666471B1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58118581A (ja) | 1981-12-29 | 1983-07-14 | Otsuka Pharmaceut Co Ltd | ジベンゾ−p−ジオキシン誘導体 |
JPH05276963A (ja) * | 1992-03-31 | 1993-10-26 | Kawasaki Steel Corp | ドコサヘキサエン酸の製造方法 |
US5422350A (en) | 1992-09-10 | 1995-06-06 | Warner-Lambert Company | Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use |
KR20010098012A (ko) * | 2000-04-27 | 2001-11-08 | 이 행 우 | 감태로부터 분리된 신규 물질, 이의 추출 및 정제방법, 및항산화제로 사용하는 용도 |
JP2003277203A (ja) | 2002-03-25 | 2003-10-02 | Kumamoto Prefecture | フロロタンニン類を主成分とする抗菌剤 |
KR20040099601A (ko) * | 2003-05-19 | 2004-12-02 | 라이브켐 주식회사 | 베타-아밀로이드에 의한 신경독성 억제용 조성물 및 이를이용한 억제방법 |
-
2003
- 2003-12-05 KR KR1020030088177A patent/KR100666471B1/ko active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58118581A (ja) | 1981-12-29 | 1983-07-14 | Otsuka Pharmaceut Co Ltd | ジベンゾ−p−ジオキシン誘導体 |
JPH05276963A (ja) * | 1992-03-31 | 1993-10-26 | Kawasaki Steel Corp | ドコサヘキサエン酸の製造方法 |
US5422350A (en) | 1992-09-10 | 1995-06-06 | Warner-Lambert Company | Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use |
KR20010098012A (ko) * | 2000-04-27 | 2001-11-08 | 이 행 우 | 감태로부터 분리된 신규 물질, 이의 추출 및 정제방법, 및항산화제로 사용하는 용도 |
JP2003277203A (ja) | 2002-03-25 | 2003-10-02 | Kumamoto Prefecture | フロロタンニン類を主成分とする抗菌剤 |
KR20040099601A (ko) * | 2003-05-19 | 2004-12-02 | 라이브켐 주식회사 | 베타-아밀로이드에 의한 신경독성 억제용 조성물 및 이를이용한 억제방법 |
Non-Patent Citations (2)
Title |
---|
05276963 |
1020010098012 |
Also Published As
Publication number | Publication date |
---|---|
KR20050054667A (ko) | 2005-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102762573B (zh) | 用于在神经退行性障碍中保护脑部健康的化合物、组合物和方法 | |
Choi et al. | Antiinflammatory, analgesic and antioxidant activities of the fruit of Foeniculum vulgare | |
Rodriguez et al. | Choleretic activity and biliary elimination of lipids and bile acids induced by an artichoke leaf extract in rats | |
Cramer et al. | Enhancing sulforaphane absorption and excretion in healthy men through the combined consumption of fresh broccoli sprouts and a glucoraphanin-rich powder | |
JP2020504153A (ja) | 食欲と欲求を低下させ、満腹感を向上させ、気分を高揚させ、ストレスを低下させるための組成物 | |
MXPA04011089A (es) | Composiciones bioactivas de similla de fenogreco y metodos para extraerla misma. | |
US20080182803A1 (en) | Rubrofusarin glycoside-containing composition | |
Joshi et al. | Pharmacological evidences for antiamnesic potentials of Phyllanthus amarus in mice | |
US20110091587A1 (en) | Phase ii detoxification and antioxidant activity | |
CN107920577A (zh) | 协同饮料组合物 | |
US7514104B2 (en) | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory | |
Mani et al. | Memory-enhancing activity of Coriandrum sativum in rats | |
Du et al. | Deer antler extracts reduce amyloid-beta toxicity in a Caenorhabditis elegans model of Alzheimer's disease | |
Xu et al. | Docosahexaenoic acid enhances hippocampal insulin sensitivity to promote cognitive function of aged rats on a high-fat diet | |
Jemima et al. | Melatonin-a review on the lesser known potential nutraceutical | |
KR20160121295A (ko) | 미토콘드리아 분열 억제제를 유효성분으로 포함하는 알츠하이머성 치매 예방 또는 치료용 약학적 조성물 | |
KR101401612B1 (ko) | 석류 추출물을 유효성분으로 포함하는 스트레스성 질환의 치료 및 예방용 조성물 | |
KR100666471B1 (ko) | 치매의 예방과 개선 및 기억력 증진용 조성물 및 이를포함하는 건강보조식품 | |
JP4145659B2 (ja) | 細辛抽出物を含有する脳細胞保護及び記憶力増進用組成物 | |
EP3862011A1 (en) | Pharmaceutical composition for preventing or treating neurodegenerative diseases, containing angelica gigas nakai extract or mixed extract of angelica gigas nakai and broccoli | |
KR102120376B1 (ko) | 승마 추출물, 이의 분획물 또는 승마에서 유래된 화합물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
KR20100109691A (ko) | 얼레지 추출물을 유효성분으로 함유하는 비만억제용 조성물 | |
JP7490204B2 (ja) | 脳機能改善剤 | |
JPH11343234A (ja) | テトラヒドロクルクミン誘導体を含有する組成物 | |
JP2007520419A (ja) | 憂鬱症治療用蓮肉抽出物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130103 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140103 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150102 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160104 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170103 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180102 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190207 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200120 Year of fee payment: 14 |